Publications (2)0 Total impact
[show abstract] [hide abstract]
ABSTRACT: Purpose: To evaluate the effectiveness of the PleurX catheter in the management of recurrent non-malignant pleural effusions. Methods: All subjects who underwent a PleurX catheter placement between 2003 and 2009 were evaluated. General demographic data, time to pleurodesis, complications, and a satisfaction questionnaire were collected. The subjects were divided into two groups. Group I included patients with non-malignant effusions and group II included patients with malignant effusions. Results: A total of 64 subjects were included in the final data analysis. A total of 23 subjects were included in group I and 41 subjects were included in group II. The diagnoses in group I included congestive heart failure (CHF; 13), hepatic hydrothorax (8), traumatic bloody (1), and idiopathic exudative (1). The diagnoses in group II included lung cancer (20), breast cancer (11), colon cancer (5), prostate cancer (2), B-cell lymphoma (2), and mesothelioma (1). The time to pleurodesis was 36 ± 12 days for group II compared to 110.8 ± 41 days for group I (p < 0.0001). The mean satisfaction score was similar in both groups (3.8 ± 0.4). Time to pleurodesis was significantly shorter in hepatic hydrothorax compared to CHF (73.6 ± 9 days vs. 113 ± 36 days, p = 0.006). There was one case of exit site infection in a patient with hepatic hydrothorax. Among subjects who were alive at 3 months after the catheter removal, none had recurrence of their pleural effusion. Conclusion: The Denver catheter was effective in achieving pleurodesis in non-malignant pleural effusions. The complication rate was low and patient satisfaction was high.Chronic Respiratory Disease 06/2011; 8(3):185-91.
Article: A new subtype of Hodgkin's lymphoma, syncytial nodular sclerosing: first case report of primary small bowel lymphoma.[show abstract] [hide abstract]
ABSTRACT: Gastrointestinal lymphomas may arise as a component of systemic disease with GI involvement or primary neoplasm. The diagnosis of primary GI lymphoma requires the lack of peripheral or mediastinal lymphadenopathy, normal white blood cell count, and differential on the peripheral blood smear; tumor involvement must be predominantly in the GI tract, and no evidence of liver or spleen involvement. The small bowel accounts for approximately 9% of the GI lymphomas. We describe a first case of primary small bowel Hodgkin's lymphoma syncytial variant nodular sclerosing type. A 28-year-old man with history of long-term use of immuno-suppressive agent and steroid presents with partial obstructing abdominal-mass-causing anemia and lower gastrointestinal bleeding. The patient underwent colonoscopy because of progressive microcytic anemia. Colonoscopy revealed non-specific polyps that were non-bleeding. The patient continued to have symptoms of abdominal cramping and twitching sensation that led to serial of small bowel radiology studies which showed multiple filling defects and a partial small bowel obstruction. The patient underwent small bowel resection, which showed Hodgkin's lymphoma syncytial variant type of nodular sclerosing. This presentation is uncommon and, so far, there are less than ten cases reported with syncytial variant (SV) type of nodular sclerosing Hodgkin's lymphoma (NSHD). All of which have presentation above the diaphragm and, to our knowledge, this represents the first case that primary SV type of NSHD originated from the small intestine.Journal of Gastrointestinal Cancer 10/2009; 40(1-2):38-40.